Analysis of catecholamines and pterins in inborn errors of monoamine neurotransmitter metabolism

• Verfasst von: Jung-Klawitter, Sabine [VerfasserIn]
• Verfasst von: Kuseyri Hübschmann, Oya [VerfasserIn]
• Titel: Analysis of catecholamines and pterins in inborn errors of monoamine neurotransmitter metabolism
• Titelzusatz: from past to future
• Verf.angabe: Sabine Jung-Klawitter and Oya Kuseyri Hübschmann
• E-Jahr: 2019
• Jahr: 9 August 2019
• Umfang: 45 S.
• Fussnoten: Gesehen am 17.10.2019
• Titel Quelle: Enthalten in: Cells
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2019
• Band/Heft Quelle: 8(2019,8) Artikel-Nummer 867, 45 Seiten
• ISSN Quelle: 2073-4409
• DOI: doi:10.3390/cells8080867
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: catecholamines
• Sach-SW: electrochemical detection
• Sach-SW: fluorescence detection
• Sach-SW: HPLC
• Sach-SW: inborn errors of metabolism
• Sach-SW: MS/MS
• Sach-SW: pterins
• K10plus-PPN: 1679056352

Abstract

Inborn errors of monoamine neurotransmitter biosynthesis and degradation belong to the rare inborn errors of metabolism. They are caused by monogenic variants in the genes encoding the proteins involved in (1) neurotransmitter biosynthesis (like tyrosine hydroxylase (TH) and aromatic amino acid decarboxylase (AADC)), (2) in tetrahydrobiopterin (BH4) cofactor biosynthesis (GTP cyclohydrolase 1 (GTPCH), 6-pyruvoyl-tetrahydropterin synthase (PTPS), sepiapterin reductase (SPR)) and recycling (pterin-4a-carbinolamine dehydratase (PCD), dihydropteridine reductase (DHPR)), or (3) in co-chaperones (DNAJC12). Clinically, they present early during childhood with a lack of monoamine neurotransmitters, especially dopamine and its products norepinephrine and epinephrine. Classical symptoms include autonomous dysregulations, hypotonia, movement disorders, and developmental delay. Therapy is predominantly based on supplementation of missing cofactors or neurotransmitter precursors. However, diagnosis is difficult and is predominantly based on quantitative detection of neurotransmitters, cofactors, and precursors in cerebrospinal fluid (CSF), urine, and blood. This review aims at summarizing the diverse analytical tools routinely used for diagnosis to determine quantitatively the amounts of neurotransmitters and cofactors in the different types of samples used to identify patients suffering from these rare diseases.